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Background. Ceftriaxone-resistant (CRO-R) Escherichia coli bloodstream infections (BSIs) are common.
Methods. This is a prospective cohort of patients with E coli BSI at 14 United States hospitals between November 2020 and April
2021. For each patient with a CRO-R E coli BSI enrolled, the next consecutive patient with a ceftriaxone-susceptible (CRO-S) E coli
BSI was included. Primary outcome was desirability of outcome ranking (DOOR) at day 30, with 50% probability of worse outcomes
in the CRO-R group as the null hypothesis. Inverse probability weighting (IPW) was used to reduce confounding.
Results. Notable differences between patients infected with CRO-R and CRO-S E coli BSI included the proportion with Pitt
bacteremia score ≥4 (23% vs 15%, P = .079) and the median time to active antibiotic therapy (12 hours [interquartile range
{IQR}, 1–35 hours] vs 1 hour [IQR, 0–6 hours]; P < .001). Unadjusted DOOR analyses indicated a 58% probability (95%
confidence interval [CI], 52%–63%) for a worse clinical outcome in CRO-R versus CRO-S BSI. In the IPW-adjusted cohort, no
difference was observed (54% [95% CI, 47%–61%]). Secondary outcomes included unadjusted and adjusted differences in the
proportion of 30-day mortality between CRO-R and CRO-S BSIs (−5.3% [95% CI, −10.3% to −.4%] and −1.8 [95% CI, −6.7%
to 3.2%], respectively), postculture median length of stay (8 days [IQR, 5–13 days] vs 6 days [IQR, 4–9 days]; P < .001), and
incident admission to a long-term care facility (22% vs 12%, P = .045).
Conclusions. Patients with CRO-R E coli BSI generally have poorer outcomes compared to patients infected with CRO-S E coli
BSI, even after adjusting for important confounders.
Keywords. bacteremia; ceftriaxone; Escherichia coli; ESBL; mortality; resistance.
Escherichia coli is the most common gram-negative
pathogen recovered in bloodstream infections (BSIs) [1].
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Unfortunately, the incidence of ceftriaxone-resistant (CRO-R)
E coli BSI continues to rise in the United States (US), with
the Centers for Disease Control and Prevention estimating a
53% increase in CRO-R E coli in clinical cultures from 2012
through 2017 [2]. Extended-spectrum β-lactamase (ESBL) pro
duction is the most common mechanism of ceftriaxone resis
tance in E coli, and ceftriaxone resistance is frequently used
as a proxy for the production of ESBLs [3]. Identification of
CRO-R E coli has important treatment implications because
ESBLs hydrolyze a number of β-lactam antibiotics beyond
just ceftriaxone, limiting β-lactam treatment options [3].
Additionally, ESBL-encoding genes frequently co-circulate
with genes encoding resistance to fluoroquinolones (eg, gyrA,
parC), trimethoprim-sulfamethoxazole (TMP-SMX) (eg, sul),
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METHODS
Study Population

We conducted a prospective multicenter study of unique adult
and pediatric patients with monomicrobial E coli BSI hospital
ized at any of the 14 participating acute care facilities in the US
between 12 November 2020 and 28 April 2021 (Figure 1). A tar
get enrollment of 300 patients—150 each with CRO-R E coli
BSI and CRO-S E coli BSI—was selected to ensure at least
90% power to detect a 20% difference in desirability of outcome
ranking (DOOR) outcomes between the 2 groups, using a
2-sided exact test at the α = .05 level. For each patient with a
CRO-R E coli BSI enrolled from a participating site, the next
consecutive patient with a CRO-S E coli BSI at the same site
was also enrolled. Clinical and Laboratory Standards Institute
(CLSI) criteria were used to categorize isolates as CRO-R E
coli (ie, ceftriaxone or cefotaxime MIC ≥4 µg/mL) or CRO-S
E coli (ie, ceftriaxone or cefotaxime MIC ≤1 µg/mL) [11].
Eligibility Criteria

Patients meeting any of the following criteria were excluded
from enrollment: (1) infection with E coli isolates with ceftriax
one MICs of 2 µg/mL (ie, CLSI intermediate category); (2) in
fection with E coli exhibiting nonsusceptibility to at least 1
carbapenem agent; (3) E coli isolates not available for confirma
tory antibiotic susceptibility testing by the central laboratory;
and (4) polymicrobial BSI.
2 • OFID • Tamma et al

Microbiological Analysis

Genus and species identification of the index E coli isolate and
antimicrobial susceptibility testing were initially performed at
local microbiology laboratories. Isolates were shipped to the
central research laboratory where frozen isolates were subcul
tured twice and nonfrozen isolates once to tryptic soy agar
with 5% sheep blood and eosin-methylene blue agar.
Bacterial genus and species were confirmed by matrix-assisted
laser desorption/ionization–time-of-flight mass spectrometry
(Bruker Daltonics). Broth microdilution (BMD) was per
formed to confirm ceftriaxone MICs [12]. Isolates with ceftri
axone MICs not achieving categorical agreement (ie, MICs
not within the same susceptibility category) when comparing
local laboratory and BMD results underwent replicate BMD
testing [12].
Outcomes

The primary outcome for the analysis was DOOR based on dis
position at day 30 after collection of the index blood culture (ie,
day 1), comparing patients with CRO-R E coli versus CRO-S E
coli BSI [13]. The DOOR was reported as 4 ordinal levels as de
scribed in Table 1. Additionally, the following were evaluated:
(1) 30-day mortality; (2) postculture length of stay (ie, days
from index blood culture collection to hospital discharge, for
patients who survived until hospital discharge); (3) recurrence
of E coli BSI over the subsequent 30 days (and with an interven
ing gap of 7 days from collection of the index blood culture);
and (4) hospital readmission within 30 days (excluding patients
who died prior to or were still hospitalized at day 30).
Data Collection

Data collection occurred locally and was entered into a central,
secure, and standardized database following criteria in a de
tailed data dictionary developed to maximize valid data entry
across the 14 sites. Data cleaning and validation occurred in
real time by a central team. Local study teams were requested
to reenter outlier or conflicting data. The following information
was collected on all patients: (1) demographic data; (2) preex
isting medical conditions (Charlson Comorbidity Index
[CCI] and severe immunocompromise, defined as solid organ
or stem cell transplant, human immunodeficiency virus infec
tion, chemotherapy within 6 months, or receipt within 30
days of prednisone ≥10 mg/day or equivalent corticosteroid
dose, or tumor necrosis factor α inhibitor or other directed
monoclonal immunomodulatory antibody); (3) severity of ill
ness at the time of blood culture collection (Pitt bacteremia
score, intensive care unit [ICU] admission on day 1); (4) likely
source of BSI and adequate source control (defined as either no
source control needed or, for patients in need of source control,
drainage of infected fluid collections and removal of infected
hardware or catheters); (5) detailed antibiotic administration
including use of active antibiotic therapy (ie, antibiotics
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and aminoglycosides (eg, aminoglycoside-modifying en
zymes), further limiting antibiotic choices [3].
Retrospective studies demonstrate that CRO-R E coli BSIs
are associated with worse clinical outcomes than BSIs caused
by ceftriaxone-susceptible (CRO-S) E coli isolates [4–8]. It is
unclear, however, if poorer outcomes persist after adjustment
for confounding factors such as delays in time to active antibi
otic therapy, immunocompromise, and challenges with achiev
ing source control—all generally more prevalent in patients
infected with drug-resistant phenotypes [9]. Moreover, these
variables can be more challenging to accurately capture retro
spectively than prospectively.
Furthermore, errors in determination of minimum inhibito
ry concentrations (MICs) observed with automated susceptibil
ity testing platforms used to define ceftriaxone resistance in the
published literature can lead to misclassification of susceptibil
ity, obscuring the findings of outcomes studies [10]. Using a
prospective, multicenter cohort of patients from across the
US with comprehensive clinical data as well as microbial iso
lates available for accurate ceftriaxone MIC determination,
we sought to compare clinical outcomes of patients with
CRO-R E coli versus CRO-S E coli. These data will help inform
the impact of ceftriaxone resistance for clinical prognostication
of E coli BSI.

exhibiting in vitro susceptibility when applying CLSI criteria),
duration of active antibiotic therapy (including antibiotic ther
apy continued after hospital discharge), and use of oral stepdown therapy (ie, the discontinuation of all intravenous antibi
otic therapy on or before day 5 and transition to an active oral
antibiotic); and (6) clinical outcomes data [11, 14–16].

Table 1. Ordinal Outcomes for Desirability of Outcome Rankings in a
Cohort of 300 Patients Infected With Ceftriaxone-Resistant Versus
Ceftriaxone-Susceptible Escherichia coli Bloodstream Infections
Criteriaa,b

Category
1 (Most desirable)

Alive and no events

2

Alive and 1 event

3

Alive and at least 2 events

4 (Least desirable)

Death

Events definition
• Failure to achieve a favorable clinical response within 30 d
• New Escherichia coli bloodstream infection within 30 d
• Remaining in the hospital at day 30 and/or readmission to the same hospital
within 30 d
• Discharge to a nursing home or skilled nursing facility (if originally admitted to
the hospital from home)
a

All criteria evaluated compared to day 1, with day 1 being the first day a positive blood
culture was collected.

b

If the reason for hospital readmission was a new E coli bloodstream infection, it is counted
as a single event.

Analytic Approach

The Pearson χ2 test was used to compare proportions between
categorical variables. The Wilcoxon rank-sum test was used to
compare distributions between continuous and ordered cate
gorical variables. As it was hypothesized that patients with
CRO-R E coli BSI would be more likely to have characteristics
independently associated with poor outcomes compared to
those with CRO-S E coli BSI (eg, complex underlying medical
conditions), adjustment using inverse probability weighting
(IPW) based on propensity scores was undertaken. The follow
ing variables were selected in calculating propensity scores: age
≥65 years, preadmission location other than home, hospitalonset infection (defined as blood cultures collected on or after
day 3 of hospitalization), CCI, Pitt bacteremia score ≥4 on day
1, ICU status on day 1, severe immunocompromise, diabetes,
cirrhosis, chronic renal replacement therapy, urinary source,
and adequate source control. Patients in the CRO-R group
were weighted by the inverse of the propensity score and pa
tients in the CRO-S group were weighted by the inverse of 1 mi
nus the propensity score. A new, weighted pseudo-population
was created in which individuals in the CRO-R and CRO-S
groups were up-weighted or down-weighted to ensure that
both groups were as similar as possible for all variables in the
propensity score at baseline, except for the susceptibility of
the E coli isolate to ceftriaxone. The primary efficacy analysis
was an IPW-adjusted disposition plot illustrating the probabil
ity of outcomes at day 30. The probability that a randomly
Clinical Impact of Ceftriaxone Resistance in E coli BSIs • OFID • 3
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Figure 1. Location of the 14 hospitals (note, two hospitals located in Detroit, MI represented by a single dot) contributing patient data and clinical isolates for the current
study.

distribution of values indicated that patients with CRO-R E
coli had overall more comorbidities than patients infected
with CRO-S E coli (P = .021). There were no statistically signifi
cant differences between groups in the proportion of individu
als with specific underlying medical conditions, including the
proportions of patients with severe immunocompromise (38
[26%] vs 30 [20%], P = .27). Patients with CRO-R E coli BSI
had a nonsignificant trend toward being more acutely ill on
the day of first positive blood culture compared to patients
with CRO-S E coli BSI; the proportion of patients with
CRO-R E coli and CRO-S E coli BSI with Pitt bacteremia score
≥4 was 35 (23%) and 23 (15%), respectively (P = .079).
Common sources of E coli BSI in the cohort as a whole were
urinary (186 [62%]), intra-abdominal (29 [10%]), presumed
(after no other source was identified) intestinal translocation
(41 [14%]), and biliary (18 [6%]), with similar distributions be
tween both groups (Table 2). Adequate source control was
achieved in 117 (78%) versus 119 (79%) patients in the
CRO-R and CRO-S E coli BSI groups, respectively (P = .778).
Antibiotic Therapy

RESULTS
Overall Cohort

In total, 300 patients with E coli BSI, including 150 patients with
CRO-R E coli and 150 with CRO-S E coli, were enrolled from 14
participating sites (Table 2). The median age of participating
patients was 68 years (interquartile range [IQR], 55–76 years).
Follow-up blood cultures were obtained in 210 (70%) patients
on hospital days subsequent to the collection of the index blood
culture; of these 210 patients, 1 patient (0.5%) had a positive
follow-up blood culture.
Microbiology

In CRO-R E coli, the median ceftriaxone MIC was ≥32 µg/mL
(IQR, ≥32−≥32) versus 0.06 µg/mL (IQR, 0.03–0.06) in CRO-S
E coli. CRO-R E coli isolates were less likely to be susceptible to
several other antibiotics as compared to CRO-S isolates: aztreo
nam, 4% versus 100%; cefepime, 13% versus 100%; ciprofloxa
cin, 21% versus 85%; gentamicin, 67% versus 95%; levofloxacin,
20% versus 87%; piperacillin-tazobactam, 85% versus 98%; and
TMP-SMX, 42% versus 73%.
Baseline Characteristics

Overall, patients with CRO-R and CRO-S E coli were similar
with regard to age, sex, and race/ethnicity (Table 2). Patients
with CRO-R E coli BSI were more likely to be admitted from
nursing homes compared to those with CRO-S E coli BSI (20
[13%] vs 6 [4%], P = .013). Patients with CRO-R isolates were
also more likely to have hospital-onset BSI, compared with pa
tients with CRO-S isolates (41 [27%] vs 21 [14%], P = .004).
While the median CCI was the same in both groups, the
4 • OFID • Tamma et al

Treatment in the first 4 days after obtaining blood cultures is
summarized in Figure 2. Empiric carbapenem therapy (ie, car
bapenem agents administered within the first 2 days of collec
tion of the index blood culture) was more common in patients
with CRO-R E coli versus CRO-S E coli BSI; 81 (54%) versus 16
(11%), respectively (P < .001). In the CRO-R group, fewer pa
tients (31 [21%]) were treated empirically with ceftriaxone as
compared to the CRO-R group (65 [44%]) (P < .0001). The me
dian number of hours to active antibiotic therapy in the CRO-R
and CRO-S groups was 12 hours (IQR, 1–35 hours) and 1 hour
(IQR, 0–6 hours), respectively (P < .001). Although patients in
fected with CRO-R E coli had a longer time to receipt of active
therapy than patients infected with CRO-S E coli, a similar pro
portion in both groups was receiving active therapy by day 3
(139 [97%] vs 145 [99%], respectively, P = .24). Durations of ac
tive antibiotic therapy were similar between both groups with
the median duration of therapy (limited to patients alive be
yond day 7) at 13 days (IQR, 8–16 days) and 12 days (IQR,
8–16 days) in the CRO-R and CRO-S groups, respectively
(P = .44). Patients with CRO-R E coli were less likely to be tran
sitioned to oral therapy; 9 (6%) patients with CRO-R E coli ver
sus 60 (41%) patients with CRO-S E coli were transitioned to
oral therapy (P < .001).
Impact of Ceftriaxone Resistance on Clinical Outcomes

The DOOR outcomes at 30 days after index blood culture col
lection both before adjustment and after IPW are illustrated in
Figure 3A and 3B. In the unadjusted DOOR analysis, CRO-R
BSI had a 58% probability (95% CI, 52%–63%) for a worse clin
ical outcome than CRO-S BSI. In the IPW-adjusted DOOR
analysis no difference was seen, with CRO-R BSI having an
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selected patient with a CRO-R versus a CRO-S E coli BSI had a
less desirable DOOR was determined. A probability of 50% im
plied no difference between DOOR distributions of the 2
groups, whereas a probability >50%, with a 95% confidence in
terval (CI) that excludes 50%, implied inferiority of the CRO-R
versus CRO-S group over the other. Confidence intervals were
calculated using 4000 bootstrap resamples. The difference in
proportions and 95% CI of 30-day mortality between CRO-R
and CRO-S E coli BSI was determined. Markers of severity of
illness on the causal pathway between the exposure and out
come (eg, ICU transfer after day 1) were not included in the de
velopment of propensity scores. However, as active empiric
therapy was considered an important confounder between pa
tients infected with CRO-R and CRO-S E coli, a subgroup anal
ysis was performed in which the IPW-adjusted DOOR
probability was estimated in the subgroup of patients receiving
active empiric therapy. P values of ≤.05 were considered statis
tically significant for all analyses. All tests were 2-sided.
Analyses were performed using SAS software, version 9.4
(SAS Institute, Cary, North Carolina).

Table 2. Baseline Characteristics Comparing Patients With Escherichia coli Bloodstream Infection, by Ceftriaxone Susceptibility Status
Variable

Ceftriaxone Resistant (n = 150)

Ceftriaxone Susceptible (n = 150)

P Valuea

Age, y, median (IQR)

69 (60–73)

67 (54–78)

.788

Age ≥65 y

90 (60)

78 (52)

.163

Female sex

73 (49)

86 (57)

.133

Weight, kg, median (IQR)

80 (66–94)

75 (63–91)

.271

White

82 (55)

95 (63)

.127

Black

39 (26)

33 (22)

.417

Latino

12 (8)

11 (7)

.828

Asian

7 (5)

11 (7)

.331

22 (15)

13 (9)

.106

120 (80)

136 (91)

Nursing home

20 (13)

6 (4)

Skilled nursing facility

10 (7)

8 (5)

41 (27)

21 (14)

Race/ethnicityb

Preadmission location
Home

Hospital-onset infection
CCI score, median (IQR)

.013

2 (1–5)

2 (0–4)

.004
.021

Preexisting medical conditionsb
Coronary artery disease

21 (14)

30 (20)

.167

Congestive heart failure

25 (17)

22 (15)

.634

9 (6)

4 (3)

.156

Diabetes

53 (35)

42 (28)

.172

Cerebrovascular disease

19 (13)

21 (14)

.734

Chronic kidney disease

35 (23)

28 (19)

.321

9 (6)

3 (2)

.077

21 (14)

12 (8)

.101

9 (6)

10 (7)

.801

38 (26)

30 (20)

.269

Intensive care unit on day 1

41 (28)

39 (26)

.794

Pitt bacteremia score ≥4 on day 1

35 (23)

23 (15)

.079

Vasopressors on day 1

28 (19)

27 (18)

.881

Mechanical ventilation on day 1

25 (17)

19 (13)

.352

Change in mental status on day 1

59 (39)

46 (31)

.116

Peripheral vascular disease

Chronic renal replacement therapy
COPD
Cirrhosis
Severe immunocompromisec
Severity of illnessb

Highest peripheral WBC count on day 1, cells/mL, median (IQR)

12 600 (6800–19 200)

13 600 (7800–18 000)

Source of bacteremia
Urinary

.295
90 (60)

96 (64)

Vascular catheter

4 (3)

5 (3)

Biliary

8 (5)

10 (7)

Intra-abdominal

16 (11)

13 (9)

Pneumonia

1 (1)

4 (3)

Neutropenic fever

7 (5)

2 (1)

21 (14)

20 (13)

117 (78)

119 (79)

Primary/presumed intestinal translocationd
Adequate source control

.411

.778

Data are presented as No. (%) unless otherwise indicated.
Abbreviations: CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; WBC, white blood cell.
a

Pearson χ2 test for categorical variables; Wilcoxon rank-sum test for ordered and continuous variables.

b

Not mutually exclusive.

c

Defined by the presence of at least 1 of the following: hematopoietic stem cell transplant within the prior 12 months, chemotherapy within the prior 6 months, solid organ transplant recipient,
human immunodeficiency virus infection with a CD4 count <200 cells/µL, receipt of corticosteroids at a dose equivalent to 10 mg daily of prednisone for ≥14 days, or other immunosuppressive
therapy (ie, calcineurin inhibitors, mammalian target of rapamycin inhibitors, chemotherapy, monoclonal antibodies, or mycophenolates).

d

No alternative source identified; does not include 1 patient each with a bone and joint infection, skin and soft tissue infection, and endocarditis.

estimated 54% probability (95% CI, 47%–61%) for a worse clin
ical outcome than CRO-S BSI. The unadjusted and adjusted
differences in proportion of 30-day mortality between
CRO-R and CRO-S was −5.3% (95% CI, −10.3% to −.4%)

and −1.8 (95% CI, −6.7% to 3.2%), respectively. In the
IPW-adjusted DOOR analysis limited to patients receiving ac
tive empiric therapy, the results were very similar with CRO-R
BSI having an estimated 54% probability (95% CI, 48%–61%)

Clinical Impact of Ceftriaxone Resistance in E coli BSIs • OFID • 5
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Other/unknown

for a poorer clinical outcome than CRO-S BSI. There were 23
(26%) and 23 (22%) hospital readmissions within 30 days
among patients discharged alive in the CRO-R and CRO-S
groups, respectively. The postculture length of stay was 8
days (IQR, 5–13 days) and 6 days (IQR, 4–9 days), respectively
(P < .001). Of the 268 (89%) patients alive at day 30, 13 (10%)
and 5 (4%) remained in the hospital on day 30 (P = .037). Of
patients originally admitted to the hospital from their homes
and alive at discharge, more patients with CRO-R E coli as com
pared to patients with CRO-S E coli were transferred to longterm care facilities (22 [22%] vs 15 [12%], P = .045).

DISCUSSION

In this prospective cohort study of 300 patients with E coli BSI
from 14 hospitals across the US, patients infected with CRO-R
E coli BSI had worse clinical outcomes compared to patients in
fected with CRO-S E coli BSI in unadjusted analyses. After ad
justing for important confounders, no difference was seen in
the primary DOOR analysis. However, patients infected with
CRO-R BSI were more likely to have prolonged lengths of hos
pital stays, to remain in the hospital at day 30, and to be newly
transferred to long-term care facilities. These findings under
score the importance of judicious antibiotic use to reduce the
development of antibiotic resistance and its subsequent nega
tive impacts on patient outcomes [17].
All-cause mortality has been evaluated in existing literature
investigating outcomes associated with drug resistance.
Previous studies have demonstrated that infections exhibiting
drug-resistant phenotypes are generally associated with in
creased mortality compared to infections caused by drugsusceptible isolates [4–8]. Our investigation was not powered
to detect a mortality difference. However, all-cause mortality
was numerically higher in the CRO-R group, although this dif
ference was not statistically significant. To evaluate additional
6 • OFID • Tamma et al

factors negatively impacting the quality of life of patients infect
ed with drug-resistant organisms, we elected to use DOOR as a
primary endpoint to capture a more wide-ranging experience
of patients infected with drug-resistant pathogens [18].
Concerns with available observational studies are that they
are either missing several key variables due to their retrospec
tive nature or that they insufficiently adjust for important base
line and treatment variables independently associated with
mortality (eg, delays in time to active therapy, complex under
lying medical conditions, severe immunocompromise, ade
quate source control measures). We attempted to overcome
the first concern by enrolling a prospective cohort with com
prehensive data collection occurring in real time. Regarding
the second concern, there were differences between patients
with CRO-R E coli and CRO-S E coli at baseline. For example,
patients with CRO-R E coli tended to be more acutely ill at base
line (ie, higher Pitt bacteremia score), had risk factors increas
ing their likelihood of drug-resistant infections (ie, long-term
care facility residency), and had more underlying medical con
ditions (ie, higher CCI). By employing IPW, we reduced the
impact of the baseline differences and associated confounding
by indication between patients infected with CRO-R E coli and
CRO-S E coli BSI.
Clinicians treating patients in our study were reasonably ac
curate in predicting the antibiotic resistance phenotype on the
day of blood culture collection. Treating physicians prescribed
empiric carbapenem therapy for most patients with CRO-R E
coli and only in few patients with CRO-S E coli. This accuracy
may have contributed to the limited differences observed in
30-day mortality. In an international randomized clinical trial,
carbapenem therapy was associated with a significant decrease
in 30-day mortality in patients with CRO-R E coli BSI [19].
Patients with CRO-R E coli bacteremia who receive early carba
penem therapy may have similar 30-day mortality rates as those
with CRO-S E coli bacteremia.
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Figure 2. Antibiotic agents administered to patients with Escherichia coli bloodstream infections over the first 4 days of antibiotic therapy, by ceftriaxone susceptibility
status.
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Figure 3. Unadjusted desirability of outcome ranking (DOOR) proportions at day 30 by ceftriaxone susceptibility status (A) and inverse probability weighting–adjusted
DOOR proportions at day 30 (B), by ceftriaxone susceptibility status. Unadjusted DOOR probability: 58% (95% bootstrap confidence interval [CI], 52%–63%). Adjusted D
OOR probability: 54% (95% bootstrap CI, 47%–61%).
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prescribing and infection control practices to prevent emer
gence of antibiotic resistance, and its negative downstream
consequences.
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We decided to focus on ceftriaxone resistance rather than the
presence of specific β-lactamase genes as ceftriaxone resistance
is more reflective of the ability of a β-lactamase to hydrolyze
ceftriaxone. Moreover, as the CLSI does not endorse routine
ESBL testing and it is performed by a minority of clinical mi
crobiology laboratories [11, 20, 21], a phenotype-guided study
design is more reflective of real-world antibiotic decision mak
ing. Although clinicians often equate CRO-R E coli with ESBL
production, E coli can exhibit ceftriaxone resistance due to a
number of mechanisms including ESBL genes (eg,
blaCTX-M-15, blaSHV-12), plasmid-mediated blaampCgenes (eg,
blaDHA, blaFOX), chromosomally derepressed blaampC genes,
and hyperexpressed narrow-spectrum β-lactamase genes with
associated mutations in permeability [3].
CRO-R E coli often carry additional antimicrobial resistance
markers (eg, qnr, mutations in gyrA and sul genes) conferring
resistance to oral antibiotics such as ciprofloxacin, levofloxacin,
and TMP-SMX [22]. In our cohort, susceptibility of CRO-R E
coli isolates to fluoroquinolones and TMP-SMX was signifi
cantly lower than for CRO-S E coli isolates. The limited avail
ability of active oral treatment options likely, at least partially,
contributed to the low percentage of patients in the CRO-R E
coli group transitioned to oral therapy, when compared to
the CRO-S E coli group (6% vs 41%). Unfortunately, the lack
of suitable oral antibiotic treatment options increases the like
lihood of placement of peripherally inserted central catheters,
prolonged hospital stays, or transfer to long-term care facili
ties—further contributing to the morbidity associated with
CRO-R E coli BSI. As oral carbapenem agents are currently
in advanced phases of clinical trials, these may help alleviate
morbidity associated with CRO-R E coli BSI in the future.
There are important limitations to this work. First, although
variables expected to be independently associated with poor
outcomes for patients with E coli BSI were collected, there
were likely additional unmeasured confounders that were not
accounted for. We attempted to mitigate the impact of co
founders on clinical outcomes through IPW propensity
score–adjusted analysis. Nonetheless, residual confounding
persists. Second, the associated differential impact of specific
antibiotics on clinical outcomes could not be investigated given
the heterogeneity of antibiotic therapy prescribed to study par
ticipants. Additionally, we were likely underpowered to identi
fy some important clinical differences because of the sample
size. For example, 30-day mortality was 13% in patients with
CRO-R E coli versus 8% in those with CRO-S E coli.
In conclusion, this work shows that patients infected with
CRO-R E coli generally have worse clinical outcomes as com
pared to patients infected with CRO-S E coli. This observation
is primarily driven by host factors such as increased comorbid
ities. Furthermore, effective empiric therapy may further de
crease differences in outcomes between groups. These
findings highlight the importance of judicious antibiotic
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